Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A class of drugs already used to treat a blood disorder could be used to treat stomach and colorectal cancer, according to new research from Australia.
Called JAK inhibitors, the drugs are currently used to treat a cancer-like condition called myelofibrosis. They are also undergoing clinical trials for use as a treatment for leukaemia, lymphoma, lupus, rheumatoid arthritis and other conditions.
In the journal Molecular Cancer Therapeutics, Matthias Ernst, an associate professor at the Walter and Eliza Hall Institute of Medical Research in Parkville, Victoria, and colleagues report how they found JAK inhibitors reduce the growth of inflammation-associated stomach and colorectal cancer.
More recently, they have had some success in unravelling the complex molecular signaling that goes on in inflamed tissue, such as that which occurs in a stomach ulcer or inflammatory bowel disease, and how this might drive cancer development.
That work helped them understand the molecules that help cancer cells grow and survive, and to identify the ones that can be targeted with potential anti-cancer drugs.
In this new study, they investigated molecules known as JAK proteins, which are involved in the development of cancer in the stomach and bowel.
When they tested the effect of drugs that block the JAK proteins - known as JAK inhibitors - in mouse models of stomach and colorectal cancer, they found they slowed the growth of tumors and killed many of the cancer cells.
Thus the study provides the first evidence, in live mice, of several proteins that could serve as valuable targets for treating cancers of the digestive tract.
This is significant because JAK inhibitors are already available and have been tested in clinical trials for treating cancer-like blood disorders, as Prof. Ernst explains:
"The reason this discovery is particularly exciting is clinical trials have already shown that JAK proteins can be safely and successfully inhibited in patients."
He adds that they hope this will shorten the time it takes to bring their "research to possible clinical trials that may improve the outlook for people with stomach and bowel cancer."
Financial sponsorship for the study came from the Australian National Health and Medical Research Council, the Ludwig Institute for Cancer Research and the Victorian Government.
In December 2013, Medical News Today reported a study where researchers in Canada found a new colorectal cancer target in a stem cell gene. They discovered that switching off the gene stopped the cancer stem cells from renewing themselves, a find that could lead to treatments that shut the cancer down.
Written by Catharine Paddock PhD
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Therapeutic Inhibition of Jak Activity Inhibits Progression of Gastrointestinal Tumors in Mice; Emma Stuart, Michael Buchert, Tracy Putoczki, Stefan Thiem, Ryan Farid, Joachim Elzer, Dennis Huszar, Paul M. Waring, Toby J. Phesse, and Matthias Ernst; Molecular Cancer Therapeutics, online 7 January 2014; DOI:10.1158/1535-7163.MCT-13-0583-T; Abstract.
Additional source: Walter and Eliza Hall Institute news release, 4 February 2014.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Paddock, Catharine. "Stomach and colorectal cancers may be treatable with existing drug." Medical News Today. MediLexicon, Intl., 5 Feb. 2014. Web.
9 Mar. 2014. <http://www.medicalnewstoday.com/articles/272195>
Paddock, C. (2014, February 5). "Stomach and colorectal cancers may be treatable with existing drug." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/272195.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.